The Conference for Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of ...

| Real-world evidence lets us see how HIV medicines work in real life, helping HCPs provide better care and improving ...

LEN is a first-in-class, long-acting HIV-1 capsid inhibitor that disrupts multiple stages of the viral replication cycle. By ...